コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 Drug resistance is a major impediment in medical oncology.
2 ited for supporting therapeutic decisions in medical oncology.
3 hallenges posed by this emerging paradigm in medical oncology.
4 ave had a substantial impact on the field of medical oncology.
5 oming integrated into the practice of modern medical oncology.
6 anding possible adverse drug interactions in medical oncology.
7 os were mailed to ASCO members who practiced medical oncology.
8 d, value-oriented approach in hematology and medical oncology.
9 n oncologists and hematologists who practice medical oncology.
10 linical Oncology and the European Society of Medical Oncology (2004-09) for relevant clinical trials.
11 nazi Jewish women with breast cancer seen at medical oncology and genetic counseling clinics in New Y
14 iplinary group (surgery, radiation oncology, medical oncology, and pathology) and were offered three
15 erican Board of Internal Medicine recognized medical oncology as a subspecialty, creating tensions be
16 n breast cancer clinical trials representing medical oncology, biostatistics, and correlative science
17 elligence-based solutions in the practice of medical oncology by discussing some of the related pragm
18 imaging has facilitated drug development in medical oncology by providing quantifiable and objective
19 Risk-Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline published i
21 Endocrine tumors are often overlooked in medical oncology discussions, as many of them are effect
22 In December, 2013, the European Society for Medical Oncology (ESMO) convened a consensus meeting to
23 n 2013 on behalf of the European Society for Medical Oncology (ESMO) Guidelines Working Group in Anna
24 Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have developed frameworks that q
25 Value Framework and the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Sc
26 Oncology (ASCO) and the European Society of Medical Oncology (ESMO) meetings held between 2004 and 2
27 partment of dermatology and 2 departments of medical oncology in France between January 2008 and Dece
28 ncology (ASCO) developed its own test -- the Medical Oncology In-Training Examination (MedOnc ITE) --
31 s head and neck surgery, radiation oncology, medical oncology, medical imaging, clinical pathology an
32 f experts representing hematologic oncology, medical oncology, neuro-oncology, neurology, radiation o
33 2DEC005), Tanoto Foundation Professorship in Medical Oncology, New Century Foundation Limited, Ling F
34 rvative surgery and radiation therapy and 20 medical oncology nurses were assessed for five health st
35 Group of Radiation Oncology/Working Group of Medical Oncology of the Germany Cancer Society] trial, p
38 y convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgica
39 ogy member physicians in 2006 as a voluntary medical oncology practice-based quality measurement and
40 s ASCO convened a multidisciplinary panel of medical oncology, psychiatry, nursing, hospice and palli
41 primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was fo
42 ety of Clinical Oncology convened a panel of medical oncology, radiation oncology, guideline implemen
43 Clinical Oncology (ASCO) convened a panel of medical oncology, radiation oncology, guideline implemen
44 linical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology,
46 linical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology,
47 ch identified all English-language phase III medical oncology randomized clinical trials (RCTs) publi
48 nditions was associated with reduced odds of medical oncology referral (odds ratio, 0.65; 95% CI, 0.5
49 iagnosis was associated with reduced odds of medical oncology referral and surveillance colonoscopy.
50 noembryonic antigen, clear surgical margins, medical oncology referral for stages II and III, fluorou
51 tios, lung transplantation services, complex medical oncology services, bariatric surgery services, a
52 cell lymphoma treated at the Wessex Regional Medical Oncology Unit in Southampton between 1979 and 19
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。